B/HPIV3 vectored HMPV vaccine candidate 2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for B/HPIV3 vectored HMPV vaccine candidate 2, covering 2026-04-16 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age [Phase 1]